Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies-Reference-Cited by-同舟云学术

Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies

Published:2010 Issue: Volume: Page:NA-NA
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head Neck

Author:

Badoual Cécile,Sandoval Federico,Pere Helene,Hans Stephane,Gey Alain,Merillon Nathalie,Van Ryswick Cordelia,Quintin-Colonna Françoise,Bruneval Patrick,Brasnu Daniel,Fridman Wolf H.,Tartour Eric

Publisher

Wiley

Subject

Otorhinolaryngology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hed.21346/fullpdf

Reference151 articles.

1. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients;King;N Engl J Med,1995

2. Solid cancers after bone marrow transplantation;Bhatia;J Clin Oncol,2001

3. Oral malignancies following HSCT: graft versus host disease and other risk factors;Demarosi;Oral Oncol,2005

4. Comparison of HPV infection, p53 mutation and allelic losses in post-transplant and non-posttransplant oral squamous cell carcinomas;Zhang;J Oral Pathol Med,2002

5. Squamous cell carcinoma of the tongue after bone marrow transplant and graft-versus-host disease: a case report and review of the literature;Byun;J Oral Maxillofac Surg,2008

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics;Indian Journal of Otolaryngology and Head & Neck Surgery;2024-03-10

2. Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit;Cancers;2024-01-11

3. T-Cell Infiltration and Immune Checkpoint Expression Increase in Oral Cavity Premalignant and Malignant Disorders;Biomedicines;2022-07-30

4. Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma;Radiotherapy and Oncology;2021-04

5. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents;Journal of Clinical Medicine;2020-03-03